J&J Defends Duragesic, Ortho Evra Patches

Safety of transdermal delivery system is not undermined by recent reports of adverse events with the products, the firm says. Mylan defends its own transdermal fetanyl patch, stating that FDA safety review pertains to Duragesic.

More from Archive

More from Pink Sheet